Optimizing caffeine dosing for infants with brain injury due to lack of oxygen
Dose Optimization for Novel Drugs for Infants with Hypoxic-Ischemic Encephalopathy
This study is looking at how caffeine can help protect the brains of babies with a serious condition called hypoxic-ischemic encephalopathy (HIE) while they receive cooling treatment, and it will test the best amount of caffeine to use for the best results.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-10906753 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for infants suffering from hypoxic-ischemic encephalopathy (HIE), a serious condition caused by a lack of oxygen to the brain. The study aims to develop a model to understand how caffeine behaves in the body during therapeutic hypothermia, a common treatment for HIE. By simulating different dosing regimens, the researchers hope to find the most effective caffeine dosage that can protect the brain and improve outcomes for these infants. Ultimately, the research will involve testing the optimized caffeine dosing in a small group of infants undergoing treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are infants diagnosed with hypoxic-ischemic encephalopathy who are undergoing therapeutic hypothermia.
Not a fit: Patients who do not have hypoxic-ischemic encephalopathy or are not receiving therapeutic hypothermia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved neurodevelopmental outcomes for infants with hypoxic-ischemic encephalopathy.
How similar studies have performed: Previous studies have shown that caffeine can reduce brain injury in animal models, but this approach in humans is novel and untested.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Jackson, Wesley M — Univ of North Carolina Chapel Hill
- Study coordinator: Jackson, Wesley M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.